article Open AccessTop 1% cited

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

Annals of Oncology · 2021 · Vol. 32(5) · pp. 661–672

Daniel J. McGrail✉(The University of Texas MD Anderson Cancer Center)P.G. Pilié(The University of Texas MD Anderson Cancer Center)N.U. Rashid(University of North Carolina at Chapel Hill)Leonie Voorwerk(Oncode Institute)Maarten Slagter(Oncode Institute)Marleen Kok(The Netherlands Cancer Institute)Eric Jonasch(The University of Texas MD Anderson Cancer Center)Mustafa Khasraw(Duke University)A Heimberger(The University of Texas MD Anderson Cancer Center)Bora Lim(The University of Texas MD Anderson Cancer Center)Naoto T. Ueno(The University of Texas MD Anderson Cancer Center)JK Litton(The University of Texas MD Anderson Cancer Center)Renata Ferrarotto(The University of Texas MD Anderson Cancer Center)JT Chang(The University of Texas MD Anderson Cancer Center)SL Moulder(The University of Texas MD Anderson Cancer Center)S.-Y. Lin✉(The University of Texas MD Anderson Cancer Center)

View via DOI Full-text PDF

Abstract

Our analysis failed to support application of TMB-H as a biomarker for treatment with ICB in all solid cancer types. Further tumor type-specific studies are warranted.

Cancer Immunotherapy and Biomarkers Cancer Genomics and Diagnostics Lung Cancer Treatments and MutationsMedicineBlockadeImmune checkpointCancerMutationImmune systemOncologyInternal medicineImmunologyGenetics